These results indicate that RANBP1 may modulate the outcome of therapeutic protocols by affecting the MTs’ counterpart; this may play a key role in the targeted treatment of breast cancer, where taxanes play the role of first-line chemotherapeutics [67]. Here, RANBP1 is linked to breast carcinoma.